Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

Nice rejects United Therapeutics’ cancer drug

July 15, 2016 Medical Communications, Research and Development NICE, United Therapeutics, Unituxin, neuroblastoma

The National Institute for Health and Care Excellence (Nice) rejected United Therapeutics’ (Nasdaq: UTHR) Unituxin (dinutuximab) in combination therapy to …
News

Bayer adds extra $2 billion to Monsanto bid

July 15, 2016 Medical Communications, Sales and Marketing Bayer, monsanto

German pharma company Bayer (ETR: BAYN) have upped their bid for Monsanto (NYSE: MON) to $64 billion, putting pressure on …
News

Busy week at Juno Therapeutics ends with takeover of RedoxTherapies

July 15, 2016 Medical Communications, Research and Development, Sales and Marketing juno therapeutics, redoxtherapies, takeover, vipadenant

Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.
News
teva_copy

Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports

July 15, 2016 Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal

Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …
News
lab

Shares drop at Santhera after FDA requires more trial data DMD drug

July 15, 2016 Medical Communications, Research and Development Duchenne Muscular Dystrophy, FDA, santhera

Santhera Pharmaceuticals (SIX: SANN) has seen shares fall as much as 38% after the US Food and Drug Administration (FDA) …
News
celgene_1_02

Celgene says its Revlimid gets European approval to treat rare non-Hodgkin’s lymphoma

July 15, 2016 Medical Communications, Research and Development, Sales and Marketing Celgene, European Commission, Revlimid, drug approval, drug trial, oncology

Celgene (Nasdaq: CELG) said the European Commission (EC) has approved Revlimid (lenalidomide) to treat a rare form of non-Hodgkin’s lymphoma. 
News
davidmeek

Ipsen’s CEO to step down, names new chief executive

July 11, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Ipsen (Euronext: IPN) said its chief executive Marc de Garidel is stepping down and will be replaced by David Meek, …
Appointment
dollars_medicines

Opponents of new Medicare reforms received far more in pharma contributions, claims report

July 11, 2016 Medical Communications, Sales and Marketing corporate donations, public citizen

A new report has emerged highlighting the extent to which opponents and critics of the Obama administration’s reforms of Medicare …
News
fda_logo-web

US FDA approves Roche Cobas HPV Test

July 8, 2016 Medical Communications, Research and Development HPV, Roche, US FDA, regulation

The US Food and Drug Administration (FDA) has approved cancer drugmaker Roche’s (VTX: ROG) cobas HPV Test. The first test …
News

Eisai criticises NICE and CDF for rare cancer ‘black hole’ in England

July 8, 2016 Medical Communications, Research and Development CDF, Eisai, NICE, black hole

Japanese pharmaceutical company Eisai (TYO: 4523) has issued a statement expressing its dismay that advanced thyroid cancer patients in England …
News
chemo-web

FDA suspends Juno Therapeutics cancer drug trial after patient deaths

July 8, 2016 Medical Communications, Research and Development FDA, juno therapeutics, patient deaths

Juno Therapeutics (NASDAQ: JUNO) has had its Phase II trial investigating JCAR015 in adult patients with relapsed or refractory B …
News

Lundbeck, Otsuka’s trial Alzheimer’s disease drug gets US FDA fast track designation

July 8, 2016 Medical Communications, Research and Development Alzheimer's disease, Lundbeck, Otsuka, US FDA, drug development, drug trial, fast track designation

H. Lundbeck A/S (CPH: LUN) and Otsuka Pharmaceutical said the US Food and Drug Administration (FDA) have granted Fast Track …
News
ablynx_flags-web

Ablynx’s RA therapy matches Roche’s Actemra in Phase IIb trial

July 7, 2016 Medical Communications, Research and Development Ablynx, Actemra, Roche

Ablynx (EBR: ABLX) has presented positive data on their rheumatoid arthritis treatment candidate, ALX-0061 (vobarilizumab), in patients with rheumatoid arthritis …
News
fda_sign_web

FDA issues new guidance on next generation sequencing

July 7, 2016 Medical Communications, Research and Development FDA, next generation sequencing, precision medicines initiative

The US Food and Drug Administration (FDA) has issued new draft guidance, as part of the Precision Medicine Initiative, on …
News

Wickham Laboratories Announces New In Vitro Pyrogenicity Testing Method

July 6, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Wickham Laboratories is pleased to announce the introduction of a new in vitro test method, the Monocyte Activation Test, for …
News
Press release
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025